Nuvectis Pharma, Inc.
NVCTNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$27.6M | −$19.8M | −$22.9M | −$19.2M | −$12.9M |
| Net income | −$26.4M | −$19.0M | −$22.3M | −$19.1M | −$12.9M |
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Equity | $18.4M | $9.7M | $12.2M | $14.2M | −$11.0M |
| EPS (diluted) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 |
| Shares out. | 23.4M | 17.8M | 14.8M | 15.2M | 4.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −143.6%
- Return on assets
- −83.4%
- Return on capital (ROCE)
- −149.8%
- Liabilities / assets
- 41.9%
- Debt / equity
- 0.72×
- Book value / share
- $0.79
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -10.83distress
- Accruals / assets
- −32.9%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2025-12A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
- Phase 1Recruitingreadout ~2026-12Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- Phase 1Recruitingreadout ~2027-03A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.4M | 10.9 | -2.6% |
| Apr 30, 2026 | 1.5M | 29.8 | -5.0% |
| Apr 15, 2026 | 1.5M | 31.3 | -2.2% |
| Mar 31, 2026 | 1.6M | 23.0 | -2.7% |
| Mar 13, 2026 | 1.6M | 30.1 | -0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Results of operationsFeb 11, 2026
- Results of operationsNov 4, 2025
- Director / officer changeSep 25, 2025
- Results of operationsAug 5, 2025
- Shareholder voteJun 13, 2025
- Other material eventMay 9, 2025
- Results of operationsMay 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 5, 2026
- 8-KFORM 8-KMay 5, 2026
- DEFA14AApr 27, 2026
- DEF 14AApr 27, 2026
- EFFECTFeb 20, 2026
- CORRESPFeb 18, 2026
- UPLOADFeb 18, 2026
- S-3FORM S-3Feb 13, 2026
- 8-KFORM 8-KFeb 11, 2026
- 10-KFeb 11, 2026
- 4OWNERSHIP DOCUMENTJan 9, 2026
- 4OWNERSHIP DOCUMENTJan 9, 2026
- 4OWNERSHIP DOCUMENTJan 9, 2026
- 4OWNERSHIP DOCUMENTJan 9, 2026
- 4OWNERSHIP DOCUMENTNov 6, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.